Global Diabetic Neuropathy Market 2014-2018

Global Diabetic Neuropathy Market 2014-2018

Category : Pharmaceuticals
Published On : May  2014
Pages : 55



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About Diabetic Neuropathy
Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission.  About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.
TechNavio's analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio's report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years. 
Key Regions
• Americas 
• EMEA        
• APAC
Key Vendors
• Eli Lilly and Co. 
• Janssen Pharmaceuticals Inc.
• Pfizer Inc.
Other Prominent Vendors
 
• Actavis plc 
• Cephalon Inc.
• MEDA Pharma GmbH & Co. KG
Key Market Driver
• Increasing Global Diabetic Population.
• For a full, detailed list, view our report.
Key Market Challenge
• High Failure Rate in Clinical Trials.
• For a full, detailed list, view our report.
Key Market Trend
• Increasing R&D Activities.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

 

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape


15.1 Competitive Scenario

15.1.1 Key News

15.1.2 Mergers and Acquisitions

15.2 Market Share Analysis 2013

15.3 Other Prominent Vendors

16. Key Vendor Analysis

16.1 Pfizer Inc.

16.1.1 Business Overview

16.1.2 Key Information

16.1.3 SWOT Analysis

16.2 Eli Lilly and Company

16.2.1 Business Overview

16.2.2 Business Segmentation

16.2.3 Key Information

16.2.4 SWOT Analysis

16.3 Janssen Pharmaceuticals Inc.

16.3.1 Business Overview

16.3.2 Key Information

16.3.3 SWOT Analysis

17. Pipeline Analysis

17.1 Phase III Analysis

17.2 Phase II Analysis

17.3 Phase I Analysis

17.4 Discontinued Projects

17.5 Projects on Hold

17.6 Promising Pipeline Molecules

17.6.1 Phase III Promising Pipeline Molecules

17.6.2 Phase II Promising Pipeline Molecules

17.7 Other First-in-class Pipeline Molecules:

18. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)

Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013

Exhibit 4: Eli Lilly and Company: Business Segmentation

Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013

Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA



Enquiry Before Buy